Endocrine Abstracts

Objective: Mortality in autoimmune Addison’s disease (AAD) is increased twofold compared to matched populations. Cardiovascular disease (CVD) is the most common cause of death, but little is known of cardiovascular morbidity. Inadequate glucocorticoid replacement has been implicated in the increased risk of CVD, but evidence is lacking. The objective of this study was to examine cardiovascular morbidity and mortality in AAD, and to investigate the effects of glucocorticoi...

Introduction: Treatment with sodium glucose co-transporter2(SGLT2) inhibitors was found to reduce the incidence of cardiovascular events in diabetic patients.Herein, we investigated the effects of long-term treatment with canagliflozin on atherosclerosis development in the aorta of Apolipoprotein E knockout (Apo-E(−/−)) mice as well as on biochemical and immunohistochemical markers related to atherosclerosis.Methods: At 4 weeks of ...

Context: Hypertension is one of the most preventable risk factors for cardiovascular disease and death. Up to 42.1% of non-Hispanic African-American subjects have hypertension. We recently found that germline ARMC5 variants may play a role in primary aldosteronism, particularly in African-Americans.Objective: We investigated a cohort of participants in the Minority Health Genomics and Translational Research Bio-Repository Database (MH-GRID) stud...

Introduction: Control of hypertension (HT) is essential to reduce cardiovascular events in diabetic patients (DPts). However, studies indicate that only 50% of DPts with treated hypertension present adequate blood pressure (BP) control. Yet Endocrine-Society-Guideline (ESG) screening for primary hyperaldosteronism (PHA) is rarely applied. Furthermore, in patients with essential hypertension (EH), longer-acting hypertension medication (HM) improves 24-hour BP when compared to r...

Aim: Antithyroid drugs (ATD) methimazole and propylthiouracil (PTU) are the drugs of choice for treatment of hyperthyroidism. Agranulocytosisis, the most severe side effect of these medications, occurs in 0.2–0.5% of patients. ATDs are used also in patients with amiodarone-induced thyrotoxicosis (AIT). Our objective was to evaluate the risk for agranulocytosis, associated with ATDs, in patients with AIT, and to compare the risk with the risk of ATD-associated agranulocyto...